AbbVie targets psychedelic-based depression drug market with $1.2 billion deal Reuters AbbVie to Acquire Gilgamesh Pharmaceuticals’ Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline PR Newswire AbbVie wagers more than $1B on Gilgamesh’s psychedelic drug Yahoo Finance AbbVie to buy Gilgamesh’s psychedelic drug for up to $1.2 billion statnews.com AbbVie to buy psychedelic drug from partner Gilgamesh Endpoints News Source link
Read More »